For all inquiries regarding Tissue Microarrays with survival data, please contact us at support@taibsbio.cn
RLN2503
询问
显微镜观察:

/

一般观察:

1.A 2 cm anterolateral incision was made at the 5th intercostal space, and the skin, subcutaneous tissue, and muscles were incised sequentially to enter the thoracic cavity.Thoracoscopic instruments were inserted through this incision. 2.Through the lung

病理学诊断:

Fragmented Left Lower Lobe Resection Specimen: 1.(Left) Lung (lower lobe): Central-type invasive adenocarcinoma, predominantly acinar pattern with focal papillary components. The tumor does not invade the pleura. 2.Bronchial stump and additionally submi

总体检查结果:

1.Fragmented left lower lobe resection specimen. A central-type tumor was identified 1 cm from the bronchial stump, measuring 4 × 3 × 2 cm. The cut surface appeared gray-white and firm. 2.Additionally submitted was a tracheal stump specimen, consisting o

年龄:75

性别:

手术日期:2021.07.14

个人历史:Healthy

家族史:Both parents deceased; siblings and children are healthy.

吸烟和饮酒史:

肿瘤大小:4cmX3cmX2cm

组织学诊断:Mediastinoscopy was not performed. On July 5, 2021, bronchoscopy was performed under general anesthesia via laryngeal mask. The glottic structures were normal, and the carina was sharp. In the left lower lobe dorsal segment, the bronchial mucosa appeared

免疫组织化学:① TTF-1 (+), Napsin A (+), SP-B (+), CK7 (+), CK18 (+), Ki-67 (+, focal ~25%), MLH1 (+), PMS2 (+), MSH6 (+), MSH2 (+), P63 (−), p40 (−), CK5/6 (−), Syn (−), CgA (−**). ② ALK (D5F3, Ventana IHC): Positive (+).

等级:II

分期:T2bN2M0

阶段:IIIA

格里森评分:/

格里森等级:/

肿瘤含量 (%):0.8

坏死内容物 (%):0

治疗方案:Regular oral administration of alectinib capsules, 600 mg once daily

疾病进展:Disease Progression 1:In August 2021, follow-up chest CT revealed a left-sided pleural effusion. In October 2021, repeat chest CT at an outside hospital showed bilateral pleural effusions, considered malignant pleural effusions secondary to recurrent pulm

跟进:Deceased(33M)

0.048094s